文献速递糖尿病

新型降糖药物的药物遗传学研究综述

Pharmacogenetics of novel glucose-lowering drugs.
PubMed 文献 · Diabetologia · 2021-02-16

本文综述了DPP-4抑制剂、GLP-1受体激动剂和SGLT2抑制剂相关基因变异与代谢反应的研究,共检索到22项研究。GLP1R变异与DPP-4抑制剂降HbA1c幅度较小及GLP-1受体激动剂减重更多相关,但多数研究样本量小、缺乏重复验证,药物遗传学指导分层处方仍需更多证据。

要点

  • GLP1R变异与DPP-4抑制剂降HbA1c反应减弱及GLP-1受体激动剂减重增加相关。
  • SLC5A2变异与恩格列净反应无关,SGLT2抑制剂药物遗传学证据有限。
  • 多数研究为候选基因设计,样本量小且缺乏重复验证,临床指导价值有限。

核心结论

  • 新型降糖药物的药物遗传学研究证据有限,尚不足以支持基于基因变异的分层处方。

研究设计与样本

  • 文献综述,从MEDLINE检索并纳入22项评估遗传变异与新型降糖药物代谢反应的研究。

主要发现

  • GLP1R基因变异与DPP-4抑制剂治疗後HbA1c降幅较小相关。
  • GLP1R变异等位基因携带者接受GLP-1受体激动剂治疗後体重下降更多。
  • KCNQ1、KCNJ11、CTRB1/2、PRKD1、CDKAL1、IL6启动子区、TCF7L2、DPP4、PNPLA3等基因变异也与DPP-4抑制剂反应相关,但缺乏重复研究。
  • CNR1、TCF7L2、SORCS1等基因变异与GLP-1受体激动剂反应相关。
  • SLC5A2变异与恩格列净反应之间未发现关联。

临床怎么用

  • 目前不应基于药物遗传学检测结果选择新型降糖药物。
  • 临床处方仍应依据现行指南和患者个体特征,而非基因变异。

局限性

  • 纳入研究遗传效应小、样本量小、统计效能有限。
  • 统计分析不充分,缺乏基因-药物交互作用分析。
  • 对混杂因素和效应修饰因素控制不足。
  • 缺乏重复验证研究,多数基于候选基因策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). In total, 22 studies were retrieved from the literature (MEDLINE). Variants of the GLP-1 receptor gene (GLP1R) were associated with a smaller reduction in HbA1c in response to DPP-4i. Variants of a number of other genes (KCNQ1, KCNJ11, CTRB1/2, PRKD1, CDKAL1, IL6 promoter region, TCF7L2, DPP4, PNPLA3) have also been related to DPP-4i response, although replication studies are lacking. The GLP1R gene was also reported to play a role in the response to GLP-1 RA, with larger weight reductions being reported in carriers of GLP1R variant alleles. There were variants of a few other genes (CNR1, TCF7L2, SORCS1) described to be related to GLP-1 RA. For SGLT2i, studies have focused on genes affecting renal glucose reabsorption (e.g. SLC5A2) but no relationship between SLC5A2 variants and response to empagliflozin has been found. The relevance of the included studies is limited due to small genetic effects, low sample sizes, limited statistical power, inadequate statistics (lack of gene-drug interactions), inadequate accounting for confounders and effects modifiers, and a lack of replication studies. Most studies have been based on candidate genes. Genome-wide association studies, in that respect, may be a more promising approach to providing novel insights. However, the identification of distinct subgroups of type 2 diabetes might also be necessary before pharmacogenetic studies can be successfully used for a stratified prescription of novel glucose-lowering drugs.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs. Diabetologia. 2021. PMID: 33594477. doi:10.1007/s00125-021-05402-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。